Pyxis Oncology appoints Ken Kobayashi as Chief Medical Officer effective Nov 27, 2023

Pyxis Oncology, Inc.

Ken Kobayashi appointed CMO effective Nov 27, 2023; will lead clinical and regulatory operations.
Dr. Kobayashi has over 25 years of oncology drug development experience, including at Pfizer, Daiichi Sankyo, and AstraZeneca.
Employment terms: $500k base salary, 40% target bonus; inducement grant of options for 1.25% of outstanding shares.
Options vest over 4 years with 25% on 1st anniversary, then monthly; additional 0.25% vesting on milestones.
Severance: 9 months base salary and health coverage if terminated without cause or for good reason.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ken Kobayashi

Chief Medical Officer

PYXS · Pyxis Oncology, Inc.

Effective: 2023-11-27
Filed: November 28, 2023, 6:59 PM ET

On November 28, 2023, Pyxis Oncology, Inc. (the “Company”) announced the appointment of Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer, effective as of November 27, 2023 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Ken Kobayashi was appointed as Chief Medical Officer at Pyxis Oncology, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

On November 28, 2023, Pyxis Oncology, Inc. (the “Company”) announced the appointment of Ken Kobayashi, M.D., F.A.C.P, as Chief Medical Officer, effective as of November 27, 2023 (the “Effective Date”).

View on SEC.gov

Pyxis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-066245

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.